After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and ...

A PD-1/VEGF bispecific antibody is a type of cancer drug designed to target both the programmed cell death protein 1, or PD-1, on immune cells and vascular endothelial growth factor, or VEGF, on tumor ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

Merck & Co Inc. (MRK) and LaNova Medicines Ltd., a privately held clinical-stage biotechnology company Thursday said Merck has ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

The German life-science and chemicals company attributed earnings growth to a recovery of its life-science segment, cost discipline and lower spending on research and development following the ...

An acquisition by Merck was “hard to resist” given the company’s long history and expertise in drug development, experience ...